glp 1 agonist new In the ATTAIN-1 phase 3, randomized trial, the use of orforglipron GLP-1 receptor agonists | How
Description
Diab Vasc
The modified polypeptide can be combined with human albumin to enhance the resistance to DPP-4 and prolong the half-life to 5-6 days
Tau beats amyloid in predicting brain atrophy in Alzheimer disease: implications for prognosis and clinical trials
FDA Approves novel, dual-targeted treatment for type 2 diabetes
